TNF Inhibitor denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your TNF Inhibitor for Medical Necessity — and How to Build Your Appeal

Tumor Necrosis Factor (TNF) inhibitors are biologics prescribed for serious inflammatory conditions — including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis — when conventional therapies have not provided adequate disease control. A medical-necessity denial from Aetna means the plan's reviewer concluded that your submitted documentation did not demonstrate that you meet the clinical criteria in Aetna's published Coverage Policy for the specific TNF inhibitor.

This is the most common denial type for biologic agents, and it is among the most successfully appealed. Medical-necessity determinations are reviewable on their clinical merits, and when the prescriber's documentation directly addresses each criterion in the insurer's policy, reversals at internal appeal are frequent.

## Federal Appeal Rights

• Internal appeal (Level 1): Submit within the deadline on your denial notice — typically 180 days. The plan must issue a decision within 30 days for prospective/pre-service claims or 72 hours for urgent care.
• Level 2 internal appeal: Some plans provide a second internal level; exhaust all internal levels before escalating.
• External review (ACA §2719 / ERISA §503): Once internal appeals are exhausted, you may request external review by an independent review organization within approximately four months of the final adverse determination. The IRO applies clinical standards and its decision binds the insurer.
• Expedited review: Request simultaneously with internal appeal if your condition is urgent or if delay would seriously jeopardize your health.

## What to Gather

• Diagnosis and severity documentation: Specialist chart notes confirming the specific diagnosis, current disease-activity measures, and objective findings (imaging, lab trends, validated scoring tools) that reflect your clinical burden.
• Conventional therapy failure history: A dated chronology of every prior medication tried — including drug name, duration, reason discontinued (inadequate response, toxicity, contraindication) — with supporting chart notes and lab data for each.
• Functional impairment evidence: Documentation of how your condition affects daily activities, work capacity, and quality of life — relevant to demonstrating severity and the need for a biologic.
• Applicable guideline alignment: Your prescriber should reference the relevant specialty society guideline organization (e.g., ACR for rheumatologic indications, AGA for GI indications) that supports biologic use at your stage of disease.
• Prescriber medical-necessity letter: The single most important document. Your specialist should state the diagnosis, disease severity, prior treatment failures with dates, and explicitly map each of Aetna's coverage criteria to the chart evidence.

## Criteria-Mapping Structure

Download Aetna's published Clinical Policy Bulletin for the specific TNF inhibitor. List every criterion — diagnosis confirmation, prior therapy requirements, disease-severity threshold, prescriber specialty. For each criterion, write the specific chart date, finding, or note that satisfies it. Submit this mapping table alongside the prescriber letter. Gaps in this mapping are why most medical-necessity denials are upheld; completeness is why they are reversed.